Evolent Health/$EVH
1D1W1MYTD1Y5YMAX
Capital at risk
About Evolent Health
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The solutions provided by the company includes: Oncology, Cardiology, Musculoskeletal, Administrative Services, Advanced Illness, Genetic Testing, Physical Medicine, Radiology, and Surgical Management.
- Ticker
- $EVH
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 4,200
- Headquarters
- Arlington, United States
- Website
- www.evolent.com
Evolent Health Metrics
BasicAdvanced
$464M
-
-$4.54
0.78
-
Price and volume
Market cap
$464M
Beta
0.78
52-week high
$9.63
52-week low
$2.10
Average daily volume
2.9M
Financial strength
Current ratio
1.239
Quick ratio
1.146
Long term debt to equity
2.528
Total debt to equity
2.532
Interest coverage (TTM)
-0.40%
Profitability
EBITDA (TTM)
49.137
Gross margin (TTM)
17.25%
Net profit margin (TTM)
-24.08%
Operating margin (TTM)
-1.33%
Effective tax rate (TTM)
-0.57%
Revenue per employee (TTM)
$500,000
Management effectiveness
Return on assets (TTM)
-0.78%
Return on equity (TTM)
-66.97%
Valuation
Price to revenue (TTM)
0.22
Price to book
1.21
Price to tangible book (TTM)
-0.53
Price to free cash flow (TTM)
5.88
Free cash flow yield (TTM)
17.01%
Free cash flow per share (TTM)
0.697
Growth
Revenue change (TTM)
-4.50%
Earnings per share change (TTM)
182.72%
3-year revenue growth (CAGR)
8.72%
10-year revenue growth (CAGR)
26.98%
3-year earnings per share growth (CAGR)
82.89%
10-year earnings per share growth (CAGR)
2.03%
What the Analysts think about Evolent Health
Analyst ratings (Buy, Hold, Sell) for Evolent Health stock.
Analyst projections of the future price of Evolent Health stock.
Bulls say / Bears say
Revenue grew 46.9% year-over-year to $652.5 million in Q2 2026, reflecting robust demand for its value-based care offerings (Zacks).
Average PMPM fee for its Performance Suite rose to $24.05 from $13.76 a year earlier, highlighting its pricing power in specialty care management (SEC).
Evolent raised its full-year 2026 revenue guidance to $2.6–2.7 billion and tightened its adjusted EBITDA outlook to $120–135 million, signaling management’s confidence in its growth trajectory (SEC).
Adjusted EBITDA margin contracted to 4.3% in Q2 2026 from 8.5% a year ago, indicating margin pressure amid rising costs (SEC).
Medical Expense Ratio climbed to 95.3% in Q2 2026 compared to 80.0% in Q2 2025, reflecting intensifying cost headwinds in its care management services (SEC).
Despite improvement, the company reported a GAAP net loss of $28.4 million in Q2 2026, underscoring persistent unprofitability on a GAAP basis (SEC).
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2026.
Evolent Health Financial Performance
Revenues and expenses
Evolent Health Earnings Performance
Company profitability
Upcoming events
No upcoming events
Evolent Health News
AllArticlesVideos
Funds containing Evolent Health
AllUSDEURGBP
Fund name | Fund size | $EVH weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.04% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.04% |
iShares Healthcare Innovation£DRDR | £1B | 0.04% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
Vanguard ESG Global All Cap£V3AB | £905M | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.